Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,083,452
  • Shares Outstanding, K 92,344
  • Annual Sales, $ 434,250 K
  • Annual Income, $ -606,640 K
  • EBIT $ -536 M
  • EBITDA $ -523 M
  • 60-Month Beta 0.56
  • Price/Sales 9.40
  • Price/Cash Flow N/A
  • Price/Book 11.75

Options Overview Details

View History
  • Implied Volatility 71.98% ( +7.73%)
  • Historical Volatility 39.16%
  • IV Percentile 90%
  • IV Rank 48.88%
  • IV High 110.63% on 04/12/24
  • IV Low 35.02% on 06/25/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 436
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 15,036
  • Open Int (30-Day) 13,508

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.32
  • Number of Estimates 11
  • High Estimate -1.09
  • Low Estimate -1.79
  • Prior Year -1.52
  • Growth Rate Est. (year over year) +13.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.45 +5.62%
on 12/19/24
50.00 -12.44%
on 12/10/24
-3.46 (-7.32%)
since 11/22/24
3-Month
41.45 +5.62%
on 12/19/24
58.14 -24.70%
on 09/24/24
-13.78 (-23.94%)
since 09/23/24
52-Week
37.02 +18.26%
on 06/18/24
60.37 -27.48%
on 09/16/24
-3.72 (-7.83%)
since 12/22/23

Most Recent Stories

More News
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE : 43.81 (-0.93%)
RARE Submits BLA to the FDA for Sanfilippo Syndrome Gene Therapy

Ultragenyx Pharmaceutical RARE announced that it has submitted a biologics license application (BLA) to the FDA for its UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome...

CTMX : 1.0900 (-1.83%)
RARE : 43.81 (-0.93%)
CSTL : 27.59 (+0.22%)
SPRO : 0.9620 (+0.72%)
Ultragenyx Pharmaceutical Inc. Doses First Patient in Pivotal Phase 3 Aspire Study for GTX-102 in Angelman Syndrome

Ultragenyx initiates Phase 3 study of GTX-102 for Angelman syndrome, assessing safety and efficacy in 120 children.Quiver AI SummaryUltragenyx Pharmaceutical Inc. announced the dosing of the first patient...

RARE : 43.81 (-0.93%)
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome

RARE : 43.81 (-0.93%)
Ultragenyx Submits Biologics License Application to the U.S. FDA for UX111 AAV Gene Therapy for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

RARE : 43.81 (-0.93%)
Insider Sale: President & CEO of $RARE (RARE) Sells 8,273 Shares

EMIL D KAKKIS, the President & CEO of $RARE ($RARE), sold 8,273 shares of the company on 12-10-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.4% of their...

RARE : 43.81 (-0.93%)
Ultragenyx to Participate in Investor Conferences in December

RARE : 43.81 (-0.93%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RARE : 43.81 (-0.93%)
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit

RARE : 43.81 (-0.93%)
Ultragenyx: Q3 Earnings Snapshot

Ultragenyx: Q3 Earnings Snapshot

RARE : 43.81 (-0.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.

See More

Key Turning Points

3rd Resistance Point 46.43
2nd Resistance Point 45.44
1st Resistance Point 44.83
Last Price 43.81
1st Support Level 43.23
2nd Support Level 42.24
3rd Support Level 41.63

See More

52-Week High 60.37
Fibonacci 61.8% 51.45
Fibonacci 50% 48.69
Fibonacci 38.2% 45.94
Last Price 43.81
52-Week Low 37.02

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar